This is extremely promising for csl112. Even if it misses primary endpoint it can still be given fda approval?
https://endpts.com/failed-pivotal-study-you-can-still-have-breakthrough-therapy-status-fda-signals-to-resverlogix/
- Forums
- ASX - By Stock
- CSL
- Dont forget about CSL112!!!
Dont forget about CSL112!!!, page-23
Featured News
Add CSL (ASX) to my watchlist
(20min delay)
|
|||||
Last
$294.65 |
Change
-0.350(0.12%) |
Mkt cap ! $142.6B |
Open | High | Low | Value | Volume |
$295.01 | $296.50 | $293.51 | $54.79M | 185.7K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
5 | 28 | $294.66 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$294.67 | 36 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
17 | 191 | 294.410 |
7 | 35 | 294.400 |
1 | 6 | 294.390 |
13 | 373 | 294.380 |
1 | 25 | 294.370 |
Price($) | Vol. | No. |
---|---|---|
294.430 | 87 | 9 |
294.450 | 36 | 3 |
294.460 | 34 | 4 |
294.470 | 37 | 4 |
294.480 | 101 | 11 |
Last trade - 14.50pm 10/10/2024 (20 minute delay) ? |
Featured News
CSL (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham, MD & CEO
James Graham
MD & CEO
Previous Video
Next Video
SPONSORED BY The Market Online